Precigen, Inc. Common Stock PGEN
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-13T18:52:58.358Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-13T18:52:55.2404087Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-13T18:52:56.861057+00:00
Precigen, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 7.46 | 131.2% | 66.0% | 2.26 | 450.2% | 61.8% |
| 25Δ | 6.96 | 123.4% | 56.0% | 2.65 | 399.5% | 54.1% |
| 30Δ | 6.46 | 115.5% | 46.0% | 3.04 | 348.8% | 46.5% |
| 35Δ | 5.96 | 107.7% | 36.0% | 3.43 | 298.2% | 38.8% |
| 40Δ | 5.45 | 99.9% | 26.1% | 3.82 | 247.5% | 31.1% |
| 45Δ | 4.98 | 93.0% | 16.8% | 4.21 | 196.8% | 23.4% |
| 50Δ | 4.80 | 95.7% | 15.1% | 4.61 | 146.1% | 15.8% |
| 55Δ | 4.62 | 98.5% | 13.3% | 5.00 | 95.4% | 8.1% |
| 60Δ | 4.44 | 101.2% | 11.5% | |||
| 65Δ | 4.26 | 104.0% | 9.8% | |||
| 70Δ | 4.08 | 106.7% | 8.0% | |||
| 75Δ | ||||||
| 80Δ | ||||||
20Δ
- Pseudo strike
- 7.46
- IV
- 131.2%
- B/E move
- 66.0%
- Pseudo strike
- 2.26
- IV
- 450.2%
- B/E move
- 61.8%
25Δ
- Pseudo strike
- 6.96
- IV
- 123.4%
- B/E move
- 56.0%
- Pseudo strike
- 2.65
- IV
- 399.5%
- B/E move
- 54.1%
30Δ
- Pseudo strike
- 6.46
- IV
- 115.5%
- B/E move
- 46.0%
- Pseudo strike
- 3.04
- IV
- 348.8%
- B/E move
- 46.5%
35Δ
- Pseudo strike
- 5.96
- IV
- 107.7%
- B/E move
- 36.0%
- Pseudo strike
- 3.43
- IV
- 298.2%
- B/E move
- 38.8%
40Δ
- Pseudo strike
- 5.45
- IV
- 99.9%
- B/E move
- 26.1%
- Pseudo strike
- 3.82
- IV
- 247.5%
- B/E move
- 31.1%
45Δ
- Pseudo strike
- 4.98
- IV
- 93.0%
- B/E move
- 16.8%
- Pseudo strike
- 4.21
- IV
- 196.8%
- B/E move
- 23.4%
50Δ
- Pseudo strike
- 4.80
- IV
- 95.7%
- B/E move
- 15.1%
- Pseudo strike
- 4.61
- IV
- 146.1%
- B/E move
- 15.8%
55Δ
- Pseudo strike
- 4.62
- IV
- 98.5%
- B/E move
- 13.3%
- Pseudo strike
- 5.00
- IV
- 95.4%
- B/E move
- 8.1%
60Δ
- Pseudo strike
- 4.44
- IV
- 101.2%
- B/E move
- 11.5%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 4.26
- IV
- 104.0%
- B/E move
- 9.8%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 4.08
- IV
- 106.7%
- B/E move
- 8.0%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 94.50% | |
| 101.04% | |
| 82.36% | |
| 101.25% | |
| 109.66% | |
| 100.77% | |
| 109.21% | |
| 103.46% | |
| 90.54% | |
| 104.77% |
Biotechnology
PHAT
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company is…
More →PHVS
Pharvaris NV, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of rare disease therapies. The company is headquartered in Leiden, the…
More →PLX
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary…
More →PRAX
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. The…
More →PRLD
Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized to target key…
More →PRME
Prime Medicine, Inc. is a pioneering biotechnology company specializing in genetic medicine through its proprietary Prime Editing technology, which enables precise DNA…
More →